Press releases

Regensburg Center for Interventional Immunology adopts LUMICKS’ z-Movi® Cell Avidity Analyzer

In its effort to develop effective cellular immunotherapies for cancer treatment, the Regensburg Center for Interventional Immunology (RCI) in Germany has purchased LUMICKS’ z-Movi®. The placement highlights the promise of measuring cell avidity between immune cells and their tumor targets to improve the selection of CARs and accelerate the development…
Press releases

LUMICKS Raises $93 Million in Series D Financing

Backed by global investor syndicate led by new investors Farallon Capital Management and Lauxera Capital Partners along with Softbank Fund 2, funds and accounts advised by T. Rowe Price Associates, Parian Global Management, Gilde Healthcare, Pura Vida Investments, and Irving Investors. Amsterdam, the Netherlands – April 16, 2021 – LUMICKS,…
Kassandra Barbetsea
15 April 2021
Press releases

LUMICKS enters collaboration with LAVA Therapeutics to characterize its tumor-specific γδ T-cell engagers

In their quest of creating safe and effective immunotherapy cancer treatments, LUMICKS and LAVA Therapeutics joined forces. The partnership aims to evaluate the efficacy of various tumor-specific γδ T-cell engagers based on the resulting binding strengths (cell avidity) between T cells and tumors, measured with LUMICKS newly installed z-Movi® Cell…
Kassandra Barbetsea
4 December 2020
Press releases

Introduction of LUMICKS consumables and script-sharing platform to facilitate faster, easier, and more reproducible Dynamic Single-Molecule analysis

In a move to broadly unlock Dynamic Single-Molecule (DSM) analysis, LUMICKS simultaneously launched two major initiatives: a new business line for reagents, biochemistry kits, and services, as well as its Harbor platform for sharing of DSM scripts. These new resources dramatically simplify the experimental workflow and make DSM analysis accessible…
Kassandra Barbetsea
2 October 2020
LUMICKS enters collaboration with Glycostem to enhance NK cell-mediated immunotherapyPress releases

LUMICKS enters collaboration with Glycostem to enhance NK cell-mediated immunotherapy

We are excited to announce that LUMICKS has entered into a collaboration with Glycostem Therapeutics, the Netherlands, to improve immunotherapeutic drug development. By quantifying binding strength between immune and cancer cells using the unique z-Movi® Cell Avidity Analyzer, Glycostem exploits the predictiveness of avidity in finding the best NK-cell population…
Department of Biochemistry, University of CambridgePress releases

New Centre of Excellence in Dynamic Single-Molecule Analysis for Accelerated Drug Discovery in collaboration with AstraZeneca and the University of Cambridge

The center will be based around LUMICKS’ C-Trap® optical tweezers–fluorescence microscope, which for the first time enables real-time observation and probing of biomolecular interactions. The approach will be pioneered in several pharmacology and biology assays with the aim of accelerating the discovery of potential new drugs.

Join our newsletter

Join our newsletter

Get exclusive news on the latest publications, product developments, events and breakthrough science.

By agreeing to receive marketing communications, you subscribe to our newsletter. You can change your mind at any time by clicking the unsubscribe link in any marketing email you receive from us. By submitting the form you agree to LUMICKS' privacy policy.

Download our webinar recording:

 

Download our Cell Therapy (CAR-T, TCR, NK) applications deck